Leap Therapeutics, Inc. (LPTX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company navigates the complex world of cancer therapeutics? Leap Therapeutics, Inc. (LPTX), a company focused on developing targeted and immuno-oncology therapeutics, has been making significant strides in this field. But how exactly does this company operate, and what makes it tick? Keep reading to explore its history, ownership structure, mission, operational mechanisms, and revenue generation strategies, offering a comprehensive understanding of Leap Therapeutics and its role in the biopharmaceutical industry.

Leap Therapeutics, Inc. (LPTX) History

Leap Therapeutics, Inc. Founding Timeline

Year established

Leap Therapeutics was founded in 2011.

Original location

The company is headquartered in Cambridge, Massachusetts.

Founding team members

Although specific names of the founding team members are not widely publicized, Leap Therapeutics was established by a group of individuals with expertise in drug development and oncology.

Initial capital/funding

Details on the initial capital and funding sources from 2011 are not specified in the available search results.

Leap Therapeutics, Inc. Evolution Milestones

Leap Therapeutics, Inc. Transformative Moments

• Strategic Partnerships: Collaborations with larger pharmaceutical companies like BeiGene have been pivotal. These partnerships provided not only financial resources but also expertise in drug development and commercialization.
• Clinical Trial Progress: Advancing DKN-01 through various phases of clinical trials has been critical. Positive data readouts have often led to increased investor confidence and further funding opportunities.
• Focus on DKN-01: Concentrating efforts on DKN-01 as the lead drug candidate has allowed Leap Therapeutics to target specific cancer pathways and refine its therapeutic approach.
• FDA Clearances: Receiving FDA clearance for IND applications, such as the FLOTILLA-2 trial, marks significant regulatory milestones that can greatly influence the company's future prospects.

To gain more insights into the investors and their motivations, check out this profile: Exploring Leap Therapeutics, Inc. (LPTX) Investor Profile: Who’s Buying and Why?

Leap Therapeutics, Inc. (LPTX) Ownership Structure

Leap Therapeutics, Inc. has a mixed ownership structure, featuring a combination of institutional, insider, and retail investors. Understanding this breakdown is crucial for investors seeking insights into the company's governance and strategic direction.

Leap Therapeutics, Inc.'s Current Status

Leap Therapeutics, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol LPTX. This means that its shares are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC).

Leap Therapeutics, Inc.'s Ownership Breakdown

The ownership of Leap Therapeutics is distributed among various types of shareholders. While specific percentages can fluctuate due to ongoing market activity, recent data from 2024 filings offers a snapshot of the ownership structure:

These figures are approximate and based on the most recent filings and publicly available information from the 2024 fiscal year. For more detailed and up-to-date information, refer to Leap Therapeutics' SEC filings, such as 10-K and proxy statements.

Leap Therapeutics, Inc.'s Leadership

The leadership team is responsible for the strategic direction and operational management of the company. As of April 2025, key members of the leadership team include:

• Douglas E. Onsi: President and Chief Executive Officer
• Sam Saks: Chief Financial Officer

These individuals, along with other members of the executive team and board of directors, guide Leap Therapeutics in its mission to develop and commercialize novel therapeutics. Additional details about the leadership team can be found on Leap Therapeutics' official website and in their SEC filings.

To gain further insights into the company's financial stability, see this analysis: Breaking Down Leap Therapeutics, Inc. (LPTX) Financial Health: Key Insights for Investors

Leap Therapeutics, Inc. (LPTX) Mission and Values

Leap Therapeutics is dedicated to developing targeted therapies that combine innovative science and patient-centric approaches to improve outcomes for people living with cancer. The company values innovation, collaboration, and a commitment to making a meaningful difference in patients' lives.

Leap Therapeutics' Core Purpose

Official mission statement

Leap Therapeutics' mission is to develop novel therapeutics that treat cancer through targeted or immuno-oncology approaches. The company is focused on advancing its pipeline of clinical-stage programs to address unmet medical needs in specific patient populations.

• Advancing clinical-stage programs
• Targeting specific patient populations with unmet medical needs
• Developing novel cancer therapeutics
• Employing targeted and immuno-oncology approaches

Vision statement

While a specific vision statement is not publicly available, Leap Therapeutics aims to become a leader in the development of innovative cancer therapies. This involves:

• Building a robust pipeline of novel drug candidates.
• Achieving clinical and regulatory milestones.
• Establishing strategic partnerships to expand the reach of its therapies.
• Improving the lives of cancer patients through targeted treatments.

Company slogan/tagline

Leap Therapeutics does not have a widely publicized official slogan or tagline. However, their focus on targeted therapies and improving patient outcomes suggests an implicit message centered on precision and impact in cancer treatment.

To gain more insights into Leap Therapeutics, Inc., consider exploring this resource: Exploring Leap Therapeutics, Inc. (LPTX) Investor Profile: Who’s Buying and Why?

Leap Therapeutics, Inc. (LPTX) How It Works

Leap Therapeutics is a biopharmaceutical company focused on developing targeted therapies and immuno-oncology combinations to treat cancers with unmet needs.

Leap Therapeutics, Inc.'s Product/Service Portfolio

Leap Therapeutics, Inc.'s Operational Framework

Leap Therapeutics operates through a framework centered on research, clinical development, and strategic partnerships to advance its pipeline of cancer therapies. Key aspects of its operational framework include:

• Research and Development: Focusing on identifying and developing innovative therapies that target specific cancer pathways and mechanisms.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates, including Phase 1, Phase 2, and Phase 3 studies.
• Regulatory Strategy: Working closely with regulatory agencies like the FDA to secure approvals for its therapies.
• Partnerships and Collaborations: Collaborating with other pharmaceutical companies and research institutions to expand its development capabilities and access new technologies.
• Manufacturing: Overseeing the manufacturing of its drug candidates to ensure a consistent supply for clinical trials and potential commercialization.

To gain more insights into the investors profile, check this out: Exploring Leap Therapeutics, Inc. (LPTX) Investor Profile: Who’s Buying and Why?

Leap Therapeutics, Inc.'s Strategic Advantages

Leap Therapeutics' strategic advantages stem from its targeted approach to cancer therapy and its ability to forge valuable partnerships. These advantages include:

• Targeted Therapies: Developing therapies that specifically target cancer cells or the tumor microenvironment, potentially leading to more effective treatments with fewer side effects.
• Novel Mechanisms of Action: Focusing on innovative approaches to disrupt cancer pathways, such as DKK1 inhibition with DKN-01 and Claudin18.2 targeting with FL-301.
• Strategic Collaborations: Partnering with established pharmaceutical companies to leverage their expertise and resources, accelerating the development and commercialization of its therapies.
• Experienced Management Team: Having a leadership team with a strong track record in drug development and commercialization.
• Strong Intellectual Property: Maintaining a robust patent portfolio to protect its drug candidates and technologies.

Leap Therapeutics, Inc. (LPTX) How It Makes Money

Leap Therapeutics, Inc. primarily operates as a biopharmaceutical company focused on developing targeted therapies and immuno-oncology therapeutics. Their revenue generation is heavily reliant on strategic collaborations and licensing agreements, as they do not currently have products approved for commercial sale.

Leap Therapeutics, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Leap Therapeutics' revenue streams are primarily composed of collaboration revenue. The following table illustrates the revenue breakdown based on the information available as of April 2025, reflecting the 2024 fiscal year data:

Leap Therapeutics, Inc.'s Business Economics

Leap Therapeutics' business economics are characterized by substantial research and development (R&D) expenses, typical of a clinical-stage biotech firm. Key aspects include:

• Collaboration Agreements: Revenue is generated through upfront payments, milestone payments, and potential royalties from licensing agreements with larger pharmaceutical companies.
• R&D Investments: A significant portion of their expenditure is allocated to advancing their pipeline of drug candidates through preclinical and clinical development.
• Cash Burn Rate: The company's cash burn rate is a critical factor, influenced by the pace of clinical trials and R&D activities.
• Financing Activities: Leap Therapeutics often relies on equity financing, debt, and strategic partnerships to fund operations.

Leap Therapeutics, Inc.'s Financial Performance

Leap Therapeutics' financial performance can be evaluated through the following key points:

• Revenue: In 2023, Leap Therapeutics reported total revenue of approximately $1.5 million, a decrease from $4.3 million in 2022. This revenue is derived from their collaboration agreement with BeiGene.
• R&D Expenses: Research and development expenses were $24.4 million for the year ended December 31, 2023, compared to $28.9 million for the year ended December 31, 2022.
• Net Loss: The company reported a net loss of $28.3 million for 2023, compared to a net loss of $31.9 million for 2022.
• Cash Position: As of December 31, 2023, Leap Therapeutics had cash, cash equivalents, and marketable securities totaling $46.8 million.

For an in-depth analysis, you might find this resource helpful: Breaking Down Leap Therapeutics, Inc. (LPTX) Financial Health: Key Insights for Investors

Leap Therapeutics, Inc. (LPTX) Market Position & Future Outlook

Leap Therapeutics is navigating a competitive biopharmaceutical landscape, striving to solidify its position through strategic clinical development and partnerships. The company's future hinges on the successful advancement of its pipeline and ability to capitalize on emerging market opportunities within the oncology space.

Competitive Landscape

Opportunities & Challenges

Industry Position

Leap Therapeutics operates within the highly competitive biopharmaceutical industry, specifically focusing on oncology. Its industry standing can be characterized by:

• Niche Player: Leap is a smaller company focusing on specific therapeutic areas and modalities within oncology.
• Pipeline-Driven: Its value is heavily dependent on the success of its clinical pipeline, particularly DKN-01 and other developing therapies.
• Partnership-Dependent: Strategic collaborations are crucial for Leap to advance its programs and expand its market reach.

To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Leap Therapeutics, Inc. (LPTX).